Decrease in incidence of bronchopulmonary dysplasia with erythropoietin administration in preterm infants: A retrospective study

Neonatology

Volumn 102, Issue 4, 2012, Pages 287-292

  Rayjada, Niti ^a   Barton, Lorayne ^a   Chan, Linda S ^b   Plasencia, Salvador ^a   Biniwale, Manoj ^a   Bui, Kim Chi ^a  

^a LAC USC MEDICAL CENTER   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Anemia of prematurity; Bronchopulmonary dysplasia; Erythropoietin; Neonates; Oxygen days; Prematurity; Ventilator days

Indexed keywords

DEXAMETHASONE; ERYTHROPOIETIN;

ANEMIA; ANEMIA OF PREMATURITY; BIRTH WEIGHT; CONTROLLED STUDY; GESTATIONAL AGE; HUMAN; INCIDENCE; INFANT; LUNG DYSPLASIA; MAJOR CLINICAL STUDY; MORBIDITY; OBSERVATIONAL STUDY; PREMATURITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; RISK FACTOR;

BIRTH WEIGHT; BRONCHOPULMONARY DYSPLASIA; CALIFORNIA; ERYTHROPOIETIN; FEMALE; GESTATIONAL AGE; HUMANS; INCIDENCE; INFANT; INFANT, EXTREMELY LOW BIRTH WEIGHT; INFANT, EXTREMELY PREMATURE; INFANT, NEWBORN; INJECTIONS, SUBCUTANEOUS; MALE; OXYGEN; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

ANIMALIA;

EID: 84865290468     PISSN: 16617800     EISSN: 16617819     Source Type: Journal    
DOI: 10.1159/000341615     Document Type: Review

References (27)

1. Claas MJ, Bruinse HW, van der Heide-Jalving M, Termote JUM, de Vries LS: Changes in survival and neonatal morbidities in infants with a birth weight of 750 g or less. Neonatology 2010; 98: 278-288.
2. Mulder EEM, Lopriore E, Rijken M, Walther FJ, te Pas AB: Changes in respiratory support of preterm infants in the last decade: Are we improving? Neonatology 2012; 101: 247-253.
3. Philip AGS: Bronchopulmonary dysplasia: Then and now. Neonatology 2012; 102: 1-8
4. Jobe A, Bancalari E: Bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001; 173: 1723-1729. (Pubitemid 32578778)
5. Reyburn B, Martin RJ, Prakash YS, MacFarlane PM: Mechanisms of injury to the preterm lung and airway: Implications for longterm pulmonary outcome. Neonatology 2012; 101: 345-352.
6. Wilson-Costello D, Walsh M, Langer J, Guillet R, Laptook A, Stoll B, Shankaran S, Finer N, Van Meurs K, Engle W, Das A: Impact of postnatal corticosteroid use on neurodevelopment at 18 to 22 months' adjusted age: effects of dose, timing, and risk of bronchopulmonary dysplasia in extremely low birth weight infants. Pediatrics 2009; 123:e430-e437.
7. Doyle LW, Ehrenkranz RA, Halliday HL: Dexamethasone treatment in the first week of life for preventing bronchopulmonary dysplasia in preterm infants: A systematic review. Neonatology 2010; 98: 217-224.
8. Doyle LW, Ehrenkranz RA, Halliday HL: Dexamethasone treatment after the first week of life for bronchopulmonary dysplasia in preterm infants: A systematic review. Neonatology 2010; 98: 289-296.
9. Ohls RK, Ehrenkranz RA, Wright LL, Lemons JA, Korones SB, Stoll BJ, Stark AR, Shankaran S, Donovan EF, Close NC, Das A: Effects of early erythropoietin therapy on the transfusion requirements of preterm infants below 1,250 grams birth weight: A multicenter, randomized, controlled trial. Pediatrics 2001; 108: 934-942. (Pubitemid 32947663)
10. Romagnoli C, Zecca E, Gallini F, Girlando P, Zuppa AA: Do recombinant human erythropoietin and iron supplementation increase the risk of retinopathy of prematurity? Eur J Pediatr 2000; 159: 627-628. (Pubitemid 30469453)
11. Soll RF: Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Neonatology 2012; 102: 127-129.
12. Bahlmann F, De Groot K, Spandau J, Landry A, Hertel B, Duckert T, Boehm S, Menne J, Haller H, Fliser D: Erythropoietin regulates endothelial progenitor cells. Blood 2004; 103: 921-926. (Pubitemid 38129551)
13. Heeschen C, Aicher A, Lehmann R, Fichtlscherer S, Vasa M, Urbich C, Mildner-Rihm C, Martin H, Zeiher A, Dimmeler S: Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 2003; 102: 1340-1346. (Pubitemid 36988041)
14. Ozer E, Kumral A, Ozer E, Yilmaz O, Duman N, Ozkal S, Koroglu T, Ozkan H: Effects of erythropoietin on hyperoxic lung injury in neonatal rats. Pediatr Res 2005; 58: 38-41. (Pubitemid 40967426)
15. Balasubramaniam V, Mervis C, Maxey A, Markham N, Abman S: Hyperoxia reduces bone marrow, circulating, and lung endothelial progenitor cells in the developing lung: Implications for the pathogenesis of bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol 2007; 292:L1073-L1084. (Pubitemid 47084852)
16. Burnham E, Taylor W, Quyyumi A, Rojas M, Brigham K, Moss M: Increased circulating endothelial progenitor cells are associated with survival in acute lung injury. Am J Respir Crit Care Med 2005; 172: 854-860. (Pubitemid 41369069)
17. Borghesi A, Massa M, Campanelli R, Bollani L, Tzialla C, Figar T, Ferrari G, Bonetti E, Chiesa G, de Silvestri A, Spinillo A, Rosti V, Stronati M: Circulating endothelial progenitor cells in preterm infants with bronchopulmonary dysplasia. Am J Respir Crit Care Med 2009; 180: 540-546.
18. Aher S, Ohlsson A: Late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2006; 3:CD004868.
19. Ohlsson A, Aher SM: Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2006; 3:CD004863.
20. Tempera A, Stival E, Piastra M, De Luca D, Ottaviano C, Tramontozzi P, Marconi M, Cafforio C, Marcozzi P, Rossi N, Buffone E: Early erythropoietin influences both transfusion and ventilation needs in very low birth weight infants. J Matern Fetal Neonatal Med 2011; 24: 1060-1064.
21. Haiden N, Schwindt J, Cardona F, Schwindt J, Berger A, Klebermass K, Wald M, Kohlhauser-Vollmuth C, Jilma B, Pollak A: Effects of a combined therapy of erythropoietin, iron, folate and vitamin B 12 on the transfusion requirements of extremely low birth weight infants, Pediatrics 2006; 118: 2004-2013. (Pubitemid 46393683)
22. Arcasoy M: The non-haematopoietic biological effects of erythropoietin. Br J Haematol 2008; 141: 14-31. (Pubitemid 351347536)
23. Foster DJ, Moe OW, Hsia CC: Upregulation of erythropoietin receptor during postnatal and postpneumonectomy lung growth. Am J Physiol Lung Cell Mol Physiol 2004; 287:L1107-L1115. (Pubitemid 39507186)
24. Kovar J, Willet KE, Hislop A, Sly PD: Impact of postnatal glucocorticoids on early lung development. J Appl Physiol 2005; 98: 881-888. (Pubitemid 40283668)
25. Zhang H, Garber SJ, Cui Z, Foley JP, Mohan GS, Jobanputra M, Kaplan F, Sweezey NB, Gonzales LW, Savani RC: The angiogenic factor midkine is regulated by dexamethasone and retinoic acid during alveolarization and in alveolar epithelial cells. Respir Res 2009; 10: 77.
26. Schneider JK, Gardner DK, Cordero L: Use of recombinant human erythropoietin and risk of severe retinopathy in extremely lowbirth-weight infants. Pharmacotherapy 2008; 28: 1335-1340.
27. Suk KK, Dunbar JA, Liu A, Daher NS, Leng CK, Leng JK, Lim P, Weller S, Fayard E: Human recombinant erythropoietin and the incidence of retinopathy of prematurity: A multiple regression model. J AAPOS 2008; 12: 233-238. (Pubitemid 351853461)